Cilian uses state-of-the-art molecular biology as well as genetic engineering and process engineering methods in the production of biopharmaceuticals.
At the centre of the CIBEX platform is the unicellular ciliate microorganism tetrahymena thermophila. Due to its outstanding properties, it is considered a "workhorse" in the life sciences.
In addition to the endeavour to optimise the CIBEX platform for the general production of therapeutic enzymes, Cilian is also developing therapeutic proteins in three different sectors:
Vaccines, enzymes and monoclonal antibodies
CIBEX SYSTEM
Innovative expression platform for the highly productive fabrication of protein-based biopharmaceuticals
CIFLU
Protein sub-unit vaccine for the treatment of seasonal and pandemic flu.
Ciliate Lipase
Recombinant lipase enzyme - e.g. for the treatment of exocrine pancreatic insufficiency (EPI)
CIMAB
Production of monoclonal antibodies based on the CIBEX expression system.
